Compare Moderna, Inc. (MRNA) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rivian Automotive, Inc. — how do they compare? Moderna, Inc. trades at $136.41 (market cap $54.14B), while Rivian Automotive, Inc. trades at $16.03 (market cap $23.17B). The key difference: Moderna, Inc. is far larger — about 2.3× Rivian Automotive, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | RIVN | |
|---|---|---|
Market Cap | $54.14B | $23.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $22.45 |
52-Week Low | $22.36 | $12.50 |
Enterprise Value | $50.29B | $23.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Rivian Automotive (RIVN) trades at $16.17, up 2.73% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company continues to report significant net losses but has shown improvement in revenue growth and gross profit margins, while recent news highlights strong demand for the R2 SUV and advancements in autonomy capabilities.
The outlook for RIVN hinges on successful R2 production scaling and path to profitability, with upside potential from current levels but high execution risk amid competitive EV market pressures and persistent cash burn requiring ongoing financing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
